Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This study developed a novel Hairless Rag2/Jak3 KO mouse model, which provides superior optical properties and thinner skin compared to existing models, enhancing its utility for noninvasive tumor monitoring and evaluation of anticancer therapies.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study reports no known changes in hair pigmentation associated with brentuximab vedotin, despite its various other documented adverse effects.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study reviews potential immune targets within hair follicles in alopecia areata, suggesting they may be associated with keratinocytes or melanocytes, and notes possible induction triggers like viruses and infections.

In this case study, an 8-year-old boy with alopecia totalis experienced significant hair regrowth after baricitinib treatment, suggesting KRT74 variants may influence immune dysregulation in this condition.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This letter to the editor discusses excessive hair growth observed around local β-interferon injection sites for malignant melanoma but reports no new clinical results.

In this study, mild adverse reactions to COVID-19 vaccines were reported among vaccinated staff and students, with females experiencing more reactions than males.

This review discusses the impact of immune-modifying therapies on COVID-19 vaccine responses, noting that a complete vaccine course can improve initially inadequate humoral responses among treated individuals compared to a single dose.

This study revealed distinct cellular and transcriptomic differences among various subtypes of cutaneous T-cell lymphoma, particularly highlighting characteristics unique to folliculotropic mycosis fungoides.

This report presents a case of a patient developing new multiple sclerosis while using tofacitinib for alopecia areata, noting no new comprehensive research findings.

Sentinel lymph node biopsy is recommended for all types of desmoplastic melanoma due to higher rates of nodal metastasis.

Sentinel lymph node biopsy is recommended for all types of desmoplastic melanoma due to higher rates of nodal metastasis.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

In this study, researchers identified a causal link between Epstein-Barr virus infection and clear cell renal cell carcinoma, highlighting GBP1 as a key target and suggesting finasteride as a potential inhibitor, offering a new direction for treatment strategies.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

In this study, a 49-year-old female with metastatic adrenocortical carcinoma experienced an abscopal effect following pulse electric field ablation, suggesting potential as an adjunct to systemic immunotherapy for liver tumors.

In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.

This study found that the epirubicin-docetaxel chemotherapy regimen for metastatic breast cancer resulted in a clinical response in 55% of patients, with maintained global quality of life despite some impairments.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.